Industry
Biotechnology
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Loading...
Open
0.66
Mkt cap
25M
Volume
127K
High
0.74
P/E Ratio
-3.09
52-wk high
3.25
Low
0.66
Div yield
N/A
52-wk low
0.48
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 9:04 pm
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 12:12 pm
Portfolio Pulse from Benzinga Newsdesk
July 23, 2024 | 8:24 pm
Portfolio Pulse from Benzinga Newsdesk
July 18, 2024 | 5:59 pm
Portfolio Pulse from Benzinga Newsdesk
June 12, 2024 | 12:10 pm
Portfolio Pulse from Benzinga Newsdesk
June 05, 2024 | 11:19 am
Portfolio Pulse from Avi Kapoor
June 04, 2024 | 4:54 pm
Portfolio Pulse from Vandana Singh
June 04, 2024 | 4:35 pm
Portfolio Pulse from Benzinga Newsdesk
June 04, 2024 | 4:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.